2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版)

2020-07-23 美国泌尿外科学会 J Urol. 2020 Jul 23.

2020年7月,美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的外科治疗指南修订版本。该指南循证更新进一步为良性前列腺增生所致下尿路症状的手术治疗提供更进一步的信息。

中文标题:

2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版)

英文标题:

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020.

发布机构:

美国泌尿外科学会

发布日期:

2020-07-23

简要介绍:

2020年7月,美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的外科治疗指南修订版本。该指南循证更新进一步为良性前列腺增生所致下尿路症状的手术治疗提供更进一步的信息。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=014601c0019a21a7, title=2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版), enTitle=Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020., guiderFrom=J Urol. 2020 Jul 23., authorId=0, author=, summary=2020年7月,美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的外科治疗指南修订版本。该指南循证更新进一步为良性前列腺增生所致下尿路症状的手术治疗提供更进一步的信息。, cover=https://img.medsci.cn/2020731/1596197301798_2020535.jpg, journalId=0, articlesId=null, associationId=87, associationName=美国泌尿外科学会, associationIntro=AUA成立于1902年, 是全球泌尿外科领域最具影响力的学术组织之一,在全球化的背景下,联合世界各地的泌尿专家促进了学术界的最新科学研究以及临床治疗,确保世界各地的患者都能接收到最高水平的治疗。 出版包括Journal of Urology在内的多种重要刊物。, copyright=0, guiderPublishedTime=Thu Jul 23 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年7月,美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的外科治疗指南修订版本。该指南循证更新进一步为良性前列腺增生所致下尿路症状的手术治疗提供更进一步的信息。</p> </div> </div> </div>, tagList=[TagDto(tagId=1298, tagName=前列腺增生), TagDto(tagId=34441, tagName=良性前列腺增生)], categoryList=[CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1298, guiderKeyword=前列腺增生, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=15, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4044, appHits=328, showAppHits=0, pcHits=1214, showPcHits=3714, likes=2, shares=16, comments=15, approvalStatus=1, publishedTime=Fri Jul 31 21:09:09 CST 2020, publishedTimeString=2020-07-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Jul 31 20:08:31 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 19:13:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版.pdf)])
2020 AUA指南:良性前列腺增生所致下尿路症状的外科治疗(修订版.pdf
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186068, encodeId=77e6118606899, content=有中文的就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d462827476, createdName=kt-knight, createdTime=Wed Jan 19 16:20:23 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079740, encodeId=b8cd10e97408d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Mon Dec 13 23:00:50 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064098, encodeId=5ec5106409892, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Tue Oct 26 14:44:20 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015691, encodeId=cc3d10156916e, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/2681af985ccd40b39ded51cfc32bd904/6cc1c39e053b404eaf7399f7fc051ccb.jpg, createdBy=5d105458123, createdName=冷浩厦, createdTime=Wed Sep 08 14:33:48 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011647, encodeId=5aaa101164ee4, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Thu Aug 26 10:01:46 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-01-19 kt-knight

    有中文的就好了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186068, encodeId=77e6118606899, content=有中文的就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d462827476, createdName=kt-knight, createdTime=Wed Jan 19 16:20:23 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079740, encodeId=b8cd10e97408d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Mon Dec 13 23:00:50 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064098, encodeId=5ec5106409892, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Tue Oct 26 14:44:20 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015691, encodeId=cc3d10156916e, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/2681af985ccd40b39ded51cfc32bd904/6cc1c39e053b404eaf7399f7fc051ccb.jpg, createdBy=5d105458123, createdName=冷浩厦, createdTime=Wed Sep 08 14:33:48 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011647, encodeId=5aaa101164ee4, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Thu Aug 26 10:01:46 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-12-13 ms7000000920508122

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186068, encodeId=77e6118606899, content=有中文的就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d462827476, createdName=kt-knight, createdTime=Wed Jan 19 16:20:23 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079740, encodeId=b8cd10e97408d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Mon Dec 13 23:00:50 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064098, encodeId=5ec5106409892, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Tue Oct 26 14:44:20 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015691, encodeId=cc3d10156916e, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/2681af985ccd40b39ded51cfc32bd904/6cc1c39e053b404eaf7399f7fc051ccb.jpg, createdBy=5d105458123, createdName=冷浩厦, createdTime=Wed Sep 08 14:33:48 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011647, encodeId=5aaa101164ee4, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Thu Aug 26 10:01:46 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-10-26 黄威龙

    可以的

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186068, encodeId=77e6118606899, content=有中文的就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d462827476, createdName=kt-knight, createdTime=Wed Jan 19 16:20:23 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079740, encodeId=b8cd10e97408d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Mon Dec 13 23:00:50 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064098, encodeId=5ec5106409892, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Tue Oct 26 14:44:20 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015691, encodeId=cc3d10156916e, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/2681af985ccd40b39ded51cfc32bd904/6cc1c39e053b404eaf7399f7fc051ccb.jpg, createdBy=5d105458123, createdName=冷浩厦, createdTime=Wed Sep 08 14:33:48 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011647, encodeId=5aaa101164ee4, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Thu Aug 26 10:01:46 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-09-08 冷浩厦

    不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186068, encodeId=77e6118606899, content=有中文的就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d462827476, createdName=kt-knight, createdTime=Wed Jan 19 16:20:23 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079740, encodeId=b8cd10e97408d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Mon Dec 13 23:00:50 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064098, encodeId=5ec5106409892, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Tue Oct 26 14:44:20 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015691, encodeId=cc3d10156916e, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/2681af985ccd40b39ded51cfc32bd904/6cc1c39e053b404eaf7399f7fc051ccb.jpg, createdBy=5d105458123, createdName=冷浩厦, createdTime=Wed Sep 08 14:33:48 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011647, encodeId=5aaa101164ee4, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/ef0965c7185541efa3305a2a0ebf560f/882e5df91b1d4be4b745ce3c279f526b.jpg, createdBy=a4765556053, createdName=黄威龙, createdTime=Thu Aug 26 10:01:46 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-26 黄威龙

    好!

    0

拓展阅读

2016 《良性前列腺增生症中医诊治》专家共识

中华中医药学会(CACM,China Association of Chinese Medcine) 男科分会 · 2016-10-19

良性前列腺增生中西医结合诊疗指南(试行版)

中国中西医结合学会男科专业委员 · 2017-03-20

FDA用于治疗良性前列腺增生 (BPH) 的器械的非临床和临床研究指南选择更新(草案)

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2021-10-01

2022 NICE介入治疗指南:前列腺临时置入治疗良性前列腺增生症所致下尿路症状 [IPG737]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2022-09-21

前列腺增生激光治疗上海专家共识

前列腺增生激光治疗上海专家共识专家组 · 2023-05-08